PPT-SMV 12W + PEG-IFN + RBV 24-48W **

SMV 24W PEGIFN RBV 2448W Randomisation 11 Openlabel 2070 years Japanese Chronic HCV infection Genotype 1 HCV RNA 100 000 IU ml IFNbased pretreated nonresponders No prior DAA therapy. Feature-rich tools for debugging mixed signal designs. 12/2012 Copyright © Tektronix 48W-26746-2. DPO7000C Series Oscilloscopes. DPO7354C. DPO7254C. DPO7104C. DPO7054C. Bandwidth. 3.5 GHz. 2.5 GHz. Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IFN + RBV. Randomisation. Open-label. 18-65 years. HCV genotype 1. HCV RNA > 10,000 IU/ml. Naïve (MALACHITE-I). Failure to . prior PEG-IFN + RBV. (MALACHITE-II). RBV . versus. . PEG alfa-. 2a . versus. INF + RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . + . RBV . Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IFN + RBV. Randomisation. Open-label. 18-65 years. HCV genotype 1. HCV RNA > 10,000 IU/ml. Naïve (MALACHITE-I). Failure to . prior PEG-IFN + RBV. (MALACHITE-II). Feature-rich tools for debugging mixed signal designs. 12/2012 Copyright © Tektronix 48W-26746-2. DPO7000C Series Oscilloscopes. DPO7354C. DPO7254C. DPO7104C. DPO7054C. Bandwidth. 3.5 GHz. 2.5 GHz. Karen Roberts Nutrition CNS RSCH. Karen Matthews Nutrition CNS RSCH/MARS team . Introduction. Case study. PEG. RIG. NGT. Making a decision. Discharging . Conclusion . 49 year old male. unknown primary with TxN3 . W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastroenterology 2015;148:355-66 . COMMAND GT2/3. COMMAND GT2/3 Study: . daclatasvir. + PEG-IFN . + RBV for genotype 2 or 3. DCV + PEG-IFN + RBV. N = 50. No. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label. BOSON . Study. : SOF + RBV . +. PEG-IFN . for genotypes 2 and 3. ≥ 18 years. Chronic HCV infection. Genotype 2, treatment-experienced with cirrhosis. . PEG alfa-. 2a . versus. INF RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . . RBV . versus. . PEG . B. ronchiolitis. Kunling. Shen MD.. . President. , Chinese Pediatric Society, Chinese Medical Association. Professor , . Beijing Children’s Hospital, Capital . Medical University . 1. . Pediatric respiratory viral . Mark Sulkowski, MD. Professor of Medicine. Johns Hopkins University. Baltimore Maryland 21212. Case . 57 . yo. woman with genotype 1a and bridging fibrosis. PROVE-1 study – treated with TVR x 12 . Jeffry Florian, Ph.D.. Division of Pharmacometrics. OCP/OTS/CDER. U. S. Food and Drug Administration. . www.fda.gov. Presented at . ASA 2016 . Biopharmaceutical . Section Regulatory-Industry Statistics .